There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Amneal Pharmaceuticals Inc. (AMRX) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.08, or 1.98%, to $4.13. The Amneal Pharmaceuticals Inc. has recorded 24,214 volume in the after hours trading session. Recently, Yahoo Finance discussed the stock, revealing that Amneal Receives U.S. FDA Approval for Calcium Gluconate Injection.
This NYSE-listed company operates within the Drug Manufacturers – Specialty & Generic industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $4.05 and fluctuated between $4.1000 as its day high and $3.8700 as its day low. The current market capitalization of Amneal Pharmaceuticals Inc. is $1.22B. A total of 1.1 million shares were traded on the day, compared to an average of 1.15M shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, AMRX has seen 2 BUY and 1 SELL insider trades, representing the acquisition of 78,044 and the disposition of 11,571 shares. Over the last 12 months, there were 22 BUYs and 11 SELLs from insiders. Insiders purchased 1,170,138 shares during that period but sold 4,024,419.
In the most recent transaction, BOYER ANDREW S sold 29,302 shares of AMRX for 4.13 per share on Aug 11. After the transaction, the Executive Vice President now owns 244,739 company shares. In a previous transaction on Dec 12, TPG GP A, LLC sold 3,884,600 shares at 2.34 per share. AMRX shares that Former 10% Owner owns now total 12,328,767.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for AMRX in the last 3 months, the mean price target is $5.25 with high estimates of $6.00 and low estimates of $5.00. In terms of 52-week highs and lows, AMRX has a high of $4.74 and a low of $1.24.
As of this writing, AMRX has an earnings estimate of $0.11 per share for the current quarter. EPS was calculated based on a consensus of 5 estimates, with a high estimate of $0.14 per share and a lower estimate of $0.09. The company reported an EPS of $0.12 in the last quarter, which was 20.00% higher than expectations of $0.1.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. AMRX’s latest balance sheet shows that the firm has $247.79M in Cash & Short Term Investments as of fiscal 2021. There were $2.88B in debt and $677.24M in liabilities at the time. Its Book Value Per Share was $2.07, while its Total Shareholder’s Equity was $366.97M.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for AMRX is Buy with a score of 4.20.